Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index
Wednesday, January 27, 2021 11:40AM IST (6:10AM GMT)
Company Ranked Sixth Overall and Leads the Pharmaceutical Industry in Governance of Access
Secured Industry-Leading Positions in All Three Technical Areas Evaluated
Shows Strong Performance in Health System Strengthening and Compliance
(TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021
Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D capacity building, according to the Index.
Professor from Tel Aviv University receives 2021 Blavatnik Award for Young Scientists in Israel
Professor Yossi Yovel, Associate Professor of Zoology at Tel Aviv University (TAU), is one of three Laureates to be awarded 2021 Blavatnik Awards for Young Scientists in Israel by the Blavatnik Family Foundation, the New York Academy of Sciences, and the Israel Academy of Sciences and Humanities.
Professor Yovel was recognized for his work in the area of Life Sciences and will receive $100,000.
Professor Yovel is working to bridge the gap between two of the most influential fields in biology ecology (the study of animals in their environment) and neuroscience (the study of how the brain controls actions).
£1.6 million grant awarded to advance development of MND drug candidate
Researchers from the University of Sheffield s Institute for Translational Neuroscience (SITraN) have been awarded a £1.6 million grant from the Medical Research Council (MRC). The grant will support their partnership with Aclipse Therapeutics to advance the translational development of M102 - a drug candidate for the treatment of motor neuron disease (MND).
Neuroprotective properties of M102 were discovered by SITraN researchers in 2013. Preclinical models evidenced the potential for M102 to slow down MND progression, which affects a patient s ability to walk, talk, eat and breathe.
The drug candidate activates the NRF2 (nuclear factor erythroid 2-related factor 2) and HSF1 (Heat shock factor 1) signalling pathways, which can work in combination to protect motor neurons from injury.
New study provides both good and bad news about transient ischemic attacks
Study findings released Tuesday in the
Journal of the American Medical Association (JAMA) hold both good news and bad news about transient ischemic attacks (TIAs), which are harbingers of subsequent strokes.
Sudha Seshadri, MD, professor of neurology at The University of Texas Health Science Center at San Antonio and director of the university s Glenn Biggs Institute for Alzheimer s and Neurodegenerative Diseases, is senior author of the study and senior investigator of the Framingham Heart Study, from which the findings are derived.
She said the extensive follow-up of Framingham participants over more than six decades enabled the study to present a more-complete picture of the risk of stroke to patients after a TIA.
E-Mail
Credit: Elsevier
Philadelphia, January 26, 2021 - Addiction, or substance use disorder (SUD), is a complex neurological condition that includes drug-seeking behavior among other cognitive, emotional and behavioral features. Synaptic plasticity, or changes in the way neurons communicate with one another, drives these addictive behaviors. These lasting brain changes are at the crux of why addiction is so hard to treat.
Biological Psychiatry, published by Elsevier, now shows that players in the extracellular environment - not just at neuronal interfaces - contribute to addiction plasticity. Neurons in a brain area called the nucleus accumbens are known to undergo addiction-related plasticity. Specifically, changes at synapses of medium spiny neurons (MSN), which sense the neurotransmitter dopamine, have been associated with drug-seeking and extinction behaviors.